Inventory of the use of natriuretic peptides in France;État des lieux de l'utilisation des peptides natriurétiques en France

Annales de Biologie Clinique

Volumn 69, Issue 6, 2011, Pages 653-662

  Collin Chavagnac, Delphine ^a   Aupetit, Jean François ^a   Barguil, Yann ^b   Benoit, Marie Odile ^c   Bricca, Giampero ^d   Cauliez, Bruno ^e   Cuerq, Charlotte ^d   Dehoux, Monique ^f   Jourdain, Patrick ^g   Lefevre, Guillaume ^h   Maupas Schwalm, Françoise ⁱ   Morin, Christine ^j   Oddoze, Christiane ^k   Plantin Carrenard, Emmanuelle ^l   Sapin, Vincent ^m   Schellenberg, François ⁿ  

^a CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^b Centre Hospitalier Nouméa   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g CENTRE HOSPITALIER RENÉ DUBOS   (France)

^h HÔPITAL TENON   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j Centre Hospitalier Calais   (France)

^k HÔPITAL SAINTE MARGUERITE   (France)

^l Centre Hospitalier Bourges   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ UNIVERSITY HOSPITAL OF TOURS   (France)

more..

Author keywords

BNP; Heart failure; NTproBNP; Survey

Indexed keywords

NATRIURETIC FACTOR; TROPONIN;

ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC TEST; ENDOCRINE SYSTEM EXAMINATION; EVALUATION; FRANCE; HIGH THROUGHPUT SCREENING; HUMAN; INFORMATION PROCESSING; INSTRUMENTATION; LABORATORY; METHODOLOGY; STATISTICS; UTILIZATION REVIEW;

DATA COLLECTION; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DIAGNOSTIC TESTS, ROUTINE; FRANCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LABORATORIES; NATRIURETIC PEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; TROPONIN;

EID: 82255195483     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0631     Document Type: Article

References (33)

1. Sudoh H, Kangawa K, Minamino N. A new natriuretic peptide in porcine brain. Nature 1988 ; 332 : 78-82.
2. Chen HH, Burnett TJ. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999 ; 111 : 406-16. (Pubitemid 29446883)
3. Bentzen H, Pedersen RS, Pedersen HB, Nyvad O, Pedersen EB. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clin Sci 2003 ; 104 : 303-12. (Pubitemid 36308179)
4. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NTproBNP. Eur Heart J 2005 ; 7 : 81-6. (Pubitemid 40092496)
5. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Failure 2003 ; 5 : 599-606. (Pubitemid 38043963)
6. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta 2007 ; 382 : 8-14. (Pubitemid 46782725)
7. Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-Terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency departement: comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005 ; 361 : 167-75. (Pubitemid 41382620)
8. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Departement (PRIDE) substudy. Am Heart J 2005 ; 149 : 744-50.
9. Kroll MH, Twomey PJ, Srisawadsi P. Using the single-compartment ratio model to calculate half life, NT-proBNP as an example. Clin Chim Acta 2007 ; 380 : 197-202. (Pubitemid 46498060)
10. Brandt I, Lambeir M, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006 ; 52 : 82-7. (Pubitemid 43032470)
11. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008 ; 54 : 866-73. (Pubitemid 351671597)
12. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, et al. Sucessive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Clin Res 2007 ; 26 : 875-82. (Pubitemid 350287174)
13. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007 ; 49 : 1071-8. (Pubitemid 46349497)
14. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-Terminal fragments of A and B type natriuretic peptides. Clin Chem 2004 ; 50 : 1576-88. (Pubitemid 39121226)
15. Davis M, Espiner E, Richards G. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994 ; 343 : 440-4. (Pubitemid 24059585)
16. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 ; 347 : 161-7. (Pubitemid 34764819)
17. Januzzi JL, Richards MR. An international consensus statement regarding amino-acid Pro-B-type natriuretic peptide testing: the international NT-proBNP consensus panel. Am J Cardiol 2008 ; 101 (Suppl.) : S1-96.
18. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-Terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004 ; 6 : 335-41. (Pubitemid 38253054)
19. Hinderliter AL, Blumenthal JA, O'Conner C, Adams KF, Dupree CS, Waugh RA, et al. Independent prognosis value of echocardiography and N-Terminal pro-B-type natriuretic peptide in patients with heart failure. Am Heart J 2008 ; 56 : 1191-5.
20. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan heart failure (Val-HeFT) data. Clin Chem 2006 ; 52 : 1528-38. (Pubitemid 44148316)
21. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve out come in heart failure: the STARS-BNP Multi center Study. J Am Coll Cardiol 2007 ; 49 : 1733-9. (Pubitemid 46589928)
22. McDonald K, Dahlström U, Aspromonte N, Jourdain P, Maisel A, Mueller C, et al. B type-natriuretic peptide: application in the community. Congest Heart Failure 2008 ; 14 : 12-6.
23. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004 ; 43 : 764-70. (Pubitemid 38296473)
24. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-Terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005 ; 112 : 1573-9. (Pubitemid 41324518)
25. Sanchez O, Trinquart L, Caille V, Couturaud F, Pacouret G, Meneveau N, et al. Prognostic factors for pulmonary embolism: the PREP study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010 ; 181 : 168-73.
26. Cortes R, Rosello-Lleti E, Rivera M, Martinez-Dolz L, Salvador A, Sirera R, et al. Expression of B-type natriuretic peptide forms in ischemic human hearts. Int J Cardiol 2011 ; Mar 9 [Epub ahead of print]
27. James SK, Lindahl B, Siegbahn A, StridsbergM, Venge P, Armstrong P, et al. N-Terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 2003 ; 108 : 275-81. (Pubitemid 36899016)
28. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller B, Whooley MA. N-Terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007 ; 297 : 169-76. (Pubitemid 46089733)
29. Talwar S, Squire IB, Downie PF, Mac Cullough AM, Campton MC, Davies JE, et al. Profile of plasma N-Terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000 ; 21 : 1514-21.
30. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005 ; 123 : 439-45. (Pubitemid 40315086)
31. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007 ; 53 : 866-73. (Pubitemid 46744242)
32. Shimizu H, Aono K, Masuta K.Degradation of human brain natriuretic peptide (BNP) ontact activation of blood coagulation systems. Clin Chim Acta 2001 ; 305 : 181-6. (Pubitemid 32201975)
33. Steiner J, Guglin M. BNP or NTproBNP? A clinician's perspective. Int J Cardiol 2008 ; 129 : 5-14.